Density of microvessels positive for CD105 (endoglin) is related to prognosis in meningiomas

Valeria Barresi1, Serenella Cerasoli, Enrica Vitarelli

  • 1Dipartimento di Patologia Umana, University of Messina, Messina, Italy. valeriabarresi@hotmail.com

Acta Neuropathologica
|June 28, 2007
PubMed

Insights

This study shows that CD105 is a more specific marker for assessing neo-angiogenesis in meningiomas than CD34. Higher CD105 levels correlate with tumor grade and predict survival, suggesting it as a therapeutic target.

Area of Science:

  • Neuro-oncology
  • Tumor Angiogenesis
  • Immunohistochemistry

Background:

  • Microvessel density (MVD) is a prognostic marker in many tumors, but its role in meningiomas is debated when using pan-endothelial markers.
  • Previous studies using markers like CD34 yielded conflicting results regarding MVD's prognostic value in meningiomas.

Purpose of the Study:

  • To assess microvessel density (MVD) in meningiomas using the specific neo-angiogenesis marker CD105.
  • To compare the prognostic significance of CD105-assessed MVD with CD34-assessed MVD in meningiomas.
  • To evaluate CD105 as a potential therapeutic target for meningioma treatment.

Main Methods:

  • Immunohistochemical analysis of CD105 and CD34 on 54 meningioma samples (28 WHO grade I, 26 WHO grade II) and 10 normal leptomeningeal samples.
  • Quantification of MVD as the number of vessels per mm² for both CD105 and CD34.
  • Correlation analysis between MVD, histological grade, Ki-67 labeling index, patient demographics, and survival outcomes.

Main Results:

  • CD105 was absent in normal meninges but present in 14/28 grade I and 24/26 grade II meningiomas.
  • CD34 stained more microvessels than CD105 in all samples (50.72 vs. 25.33 vessels/mm²).
  • Higher CD105 counts correlated significantly with higher tumor grade and Ki-67 LI (>4%).
  • CD105-MVD, unlike CD34-MVD, showed a significant inverse correlation with overall survival and recurrence-free survival.

Conclusions:

  • CD105 is a more specific marker for evaluating neo-angiogenesis in meningiomas compared to pan-endothelial markers like CD34.
  • CD105-assessed MVD has greater prognostic significance in meningiomas.
  • CD105 may represent a promising therapeutic target for blocking blood supply in meningiomas.

Related Concept Videos